DSDaniele Sartori

Daniele Sartori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniele Sartori has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal

    by Michele Fusaroli, Joana Félix China, D. Sartori, Valentina Giunchi, Linda Härmark, Joep Scholl, Florence van Hunsel, G. Niklas Norén, Johan Ellenius

  • Open Access

    Towards a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal

    by M. Fusaroli, J. Félix China, D. Sartori, V. Giunchi, L. Härmark, J. Scholl, F. van Hunsel, G. N. Norén, J. Ellenius

    Background: Retrieval of adverse event reports based on coded drug-event co-occurrence enables large-scale pharmacovigilance analyses, but yields candidate reports rather than validated cases, risking misinterpretation if used alone. Aim: To develop and apply a framework for identification and characterization of clinically meaningful case series in pharmacovigilance. Methods: We conducted two case studies. The first developed and refined the framework in an information-rich setting, focusing on drug-induced impulsivity across selected drugs; the second tested its applicability in a more routine, information-poor setting, focusing on drug-induced suicidality. Results: In Case 1, non-relevant reports were frequent for drugs with uncertain evidence and negative controls (≈20-40%) compared to drugs with established causal roles (4%). The emerging framework assessed relevance based on exposure, event, drug-event relationship, and population. For suspected adverse drug reactions, relevant reports were further characterized by reporter suspicion and evidentiary qualifiers supporting or refuting causality; higher suspicion was associated with more supportive qualifiers. Applied to Case 2, the framework ruled out 69% of reports as non-relevant but highlighted substantial non-assessability (17%). Conclusions: In pharmacovigilance, retrieval is not equivalent to case identification. Relevance is question-specific and shaped by how reports are captured, processed, and retrieved. This can be especially critical for emerging or bias-prone safety questions. Transparent and reproducible case definition and adjudication are essential for interpretable analyses. Graphical Code-based retrieval of drug–event co-occurrence yields a heterogeneous set of candidate reports that does not directly correspond to a clinically meaningful case series. The proposed framework separates case identification from retrieval by adjudicating relevance across exposure, event, relationship, and context, ruling out non-relevant or non-assessable reports. Relevant reports are further qualified by reporter suspicion and evidentiary features, enabling more interpretable pharmacovigilance analyses.

  • Open Access

    International Medicinal Product Information Documents: A Quantitative Content Analysis of Instructions for Preventing, Mitigating, and Monitoring Adverse Drug Reactions

    by Daniele Sartori, Michele Fusaroli, Jeffrey K. Aronson, G. Niklas Norén, Igho J. Onakpoya

    Introduction Medicinal product information documents (PIDs) detail clinical characteristics and instructions for monitoring, preventing, and mitigating adverse drug reactions (ADRs). They vary across countries, but there have been no recent international comparisons. We have therefore quantified and compared the completeness of the information given in drug labelling from different countries. Methods From the websites of 35 regulatory agencies, we retrieved the PIDs of medicinal products that were involved in signals communicated by regulators in 2014–2019. We developed a data extraction framework based on the Dose-relatedness, Time course, Susceptibility (DoTS) clinical classification of ADRs and used its implications for prevention and mitigation to score the completeness of related instructions in PIDs. To extract and classify monitoring instructions, we used a modified Systematic Instructions for Monitoring (SIM) method. PIDs had sufficiently complete instructions for prevention when the DoTS score was ≥ 5/12, and sufficiently complete monitoring instructions when the SIM score was ≥ 3/6. We used proportions of PIDs having a score ≥ 1 to determine the relative availability of clinical characteristics or instructions in a country, compared with all other countries. We quantified their pairwise disagreements using Jaccard’s distance and identified clusters with similar patterns of completeness using agglomerative hierarchical clustering. Results PIDs were available on the websites of 18 of 35 regulatory agencies. They concerned 364 distinct medicinal products, which were involved in 627 signals. Across all countries, the instructions for prevention or mitigation met sufficient completeness for a median of 30% of PIDs (IQR 28–33%), while instructions for monitoring were sufficiently complete for a median of 22% (IQR 19–25%). The information given by the European Union (EU) and Canada had the highest relative availability of clinical characteristics and prevention or mitigation instructions, with a proportion of 0.86. Canadian and EU PIDs also had the highest relative availability of monitoring instructions, with proportions of 0.79 and 0.70. Two clusters of countries showed low disagreements: Malaysia and Singapore; Australia and New Zealand. Conclusions This study suggests that PIDs often do not contain complete instructions for prevention, mitigation, and monitoring of ADRs. Extending existing regulatory cooperation globally would enable regulators to access clinical characteristics and instructions from different regions.


  • Top Cited Papers
    Open Access

    VigiBase: Resource Profile Update with a Summary of Global Patterns and Trends in Adverse Event Reports for Medicines and Vaccines

    by Judith S. Brand, Oskar Gauffin, Daniele Sartori, Michele Fusaroli, Helena Sköld, Tomas Bergvall, Lovisa Sandberg, Magnus Wallberg, Peter Hjelmström, G. Niklas Norén

    VigiBase, the WHO global database of adverse event reports for medicines and vaccines, receives information on suspected adverse effects of medicinal products from countries, regions and territories that are members of the WHO Programme for International Drug Monitoring. The database serves as a global resource for pharmacovigilance signal management and scientific development. Its initial establishment through the programme in 1968 has also contributed to the international harmonisation of adverse event report data. As of 31 December 2024, the database includes over 40 million individual case reports coded in standard terminologies (WHODrug and MedDRA®). These reports, of which ~ 80% relate to medicines and ~ 20% to vaccines, come from over 160 countries. This profile paper aims to provide an update on the database infrastructure including data capture, management and analysis tools. It also presents a summary of global patterns and trends of key report characteristics, as well as strengths and limitations of the data to offer context to users and the global pharmacovigilance community.


  • Open Access

    Correction: Charting and Sidestepping the Pitfalls of Disproportionality Analysis

    by Michele Fusaroli, Daniele Sartori, Eugène P. van Puijenbroek, G. Niklas Norén


  • Top Cited Papers
    Open Access

    Charting and Sidestepping the Pitfalls of Disproportionality Analysis

    by Michele Fusaroli, Daniele Sartori, Eugène P. van Puijenbroek, G. Niklas Norén

    Disproportionality analysis is used by many pharmacovigilance organizations for detecting and assessing signals of potential adverse drug reactions. However, its goal is often misunderstood and the approach misapplied, leading to erroneous conclusions due to neglected violated assumptions. In this paper we illustrate how simplistic use and interpretation of disproportionality analysis can lead to incorrect conclusions. Using VigiBase, the WHO global database of adverse event reports, and the Information Component disproportionality metric, we provide selected examples to highlight common sources of error that can introduce spurious disproportionalities or lead to missing important signals: confounding (by age, sex, indication, comedication), effect modification (by age), notoriety bias, masking, misclassification (by miscoding, incomplete or imprecise event retrieval), neglecting report utility, and violated independence assumption. Additionally, we present how sophisticated analyses may introduce new biases or amplify existing ones, such as collider bias or masking amplification. Due to its pitfalls, disproportionality analysis plays a supportive rather than decisive role in signal detection and assessment. Careful design and interpretation of disproportionality analysis, with appropriate subgrouping and clinical assessment, are essential. While subgrouping can mitigate some pitfalls, it reduces sample size and may introduce or amplify existing biases and needs to be used with care. Further development of tools to detect and mitigate biases in disproportionality analyses, and to assess their risk of bias, is needed.


  • Open Access

    Signals of Adverse Reactions to Herbal Medicines: Evidence and Document Analysis Based on a Scoping Review

    by Daniele Sartori, Jeffrey K. Aronson, Judith S. Brand, Oskar Gauffin, Sara Hedfors Vidlin, G. Niklas Norén, Igho J. Onakpoya

    Background To date, signals of adverse reactions to herbal medicines have not been systematically reviewed, limiting pharmacovigilance of herbal medicines because of a lack of data. Objectives We sought to analyse the available evidence on signals involving herbal medicines and to determine to what extent they had been documented at the European Union (EU) level and in the USA. Methods We used the results of a published scoping review of interventional and non-interventional studies that reported signals of adverse reactions to drugs. We assigned Anatomical Therapeutic Chemical classification to all drugs, and identified herbal medicines when they fell under the Anatomical Therapeutic Chemical V90. We ascertained the presence of the adverse reaction, or related adverse reactions, for each signal in reference documents for healthcare professionals: the US Botanical Safety Handbook and the EU monographs and US Dietary Supplement Fact Sheets; and in those for consumers: the US Dietary Supplement Label Database. We summarised the data descriptively, treating US documents as one and comparing harms across pairs of US and EU documents by signal. Documents were deemed concordant if they both included the same or related adverse reactions, or if neither did. We also compared adverse reactions across US documents for healthcare professionals with those for consumers. Results Of the 10,861 signals covered by the scoping review, 53 (0.49%) concerned herbal medicines, all based on case reports. Reference documents from both the US and EU were available for 37 signals. Most of the documents were concordant (73%), and ten (27%) were discordant: six adverse reactions were mentioned only in US documents, three only in EU monographs, and one was warned against in US documents but not in EU documents. Twenty-one signals could be followed up in the Botanical Safety Handbook and Dietary Supplement Fact Sheets. Most (68%) US documents for healthcare professionals were concordant. When the Botanical Safety Handbook and Dietary Supplement Fact Sheets did not include an adverse reaction, neither did the Dietary Supplement Label Database. However, when they did, only 20% of the labels for consumers did too. The proportion of labels mentioning adverse reactions otherwise available in documents intended for healthcare professionals ranged widely, reflecting differences across multiple labels for the same products. Conclusions Very few signals of adverse reactions from the wider scoping review concerned herbal medicines, and were all based on case reports. Information was mostly concordant across documents in the EU and USA. As manufacturers are solely responsible for the contents of the Dietary Supplement Label Database, regulatory oversight may be required to ensure that consistent and comprehensive information on the harms of herbal medicines is made available to consumers in the USA.


  • Open Access

    Strategies and Challenges in Coding Ambiguous Information Using MedDRA®: An Exploration Among Norwegian Pharmacovigilance Officers

    by Tahmineh Garmann, Hilde Samdal, Daniele Sartori, David Jahanlu, Fredrik Andersen, Elena Rocca

    Introduction The Medical Dictionary for Regulatory Activities (MedDRA®) is an international standardized medical terminology used to code various types of medical information, including safety reports of suspected adverse reactions to medicines. Quantitative studies have highlighted varying levels of coding inconsistency across MedDRA®-relevant platforms, though the possible grounds of such inconsistency remain unclear. Objective We explored the reasoning and strategies employed by pharmacovigilance officers when coding selected ambiguous adverse events to MedDRA®, categorized the types of coding inconsistencies, and explored sources of the inconsistencies. Methods Pharmacovigilance officers from the Norwegian public health sector were invited to participate in a survey-based, cross-sectional study followed by focus group interviews. The survey consisted of 11 coding tasks, with varying degrees of ambiguity, purposively sampled from the Norwegian pharmacovigilance registry. Participants selected the appropriate MedDRA® terms and graded the difficulty level of each task on a scale from 1 (least difficult) to 4 (most difficult). Terms selected by participants were compared with a Standard Term Selection (STS), agreed upon by the authors in consultation with a MedDRA® trainer. Inconsistencies with the STS were classified as omission (missing term), substitution (extra term selected in the presence of an omission), and addition (extra term selected and none omitted). In focus groups, participants discussed challenges in the coding tasks and the strategies they used to overcome them. Interview transcripts were analyzed using thematic analysis. Results In total, 26 coders (79% of the eligible population) completed the survey. Of the survey answers, 36% were identical to the STS; answers consistent with the STS varied across the specific coding tasks and did not align with the perceived difficulty of the tasks. The most common inconsistency (30% of the survey answers) arose from substituting one of multiple MedDRA® terms. Of the survey answers, 18% included omissions without substitutions, and 6% added unnecessary terms to the STS. Eight of the 26 coders (31%) participated in the focus group interviews. Focus group themes revealed that substitutions were explained by difficulties in translating lay language to medical terminology, finding accurate English translations for Norwegian medical terms, and fitting complex descriptions into MedDRA® terms. This was explained by themes related to ambiguity-resolution strategies. Themes explaining omissions included strategies for resolving ambiguity, contextual thinking, causal and pharmacological reasoning in the coding process, and information categorization. Conclusions Tailored training programs and clear institutional guidelines are needed to target the sources of coding inconsistencies suggested by this study.


  • Open Access

    Charting the pitfalls of disproportionality analysis

    by Michele Fusaroli, Daniele Sartori, Eugène van Puijenbroek, G. Niklas Norén

    Background: Disproportionality analysis is used by many pharmacovigilance organizations for detecting and assessing signals of potential adverse drug reactions. However, its goal is often misunderstood and the approach misapplied, leading to erroneous conclusions due to neglected violated assumptions.Objective: To illustrate how the simplistic use and interpretation of disproportionality analysis can lead to incorrect conclusions. Methods: Using VigiBase, the WHO global database of adverse event reports, and the Information Component disproportionality metric, we provided selected examples to highlight common sources of error that can introduce spurious associations or lead to missing important signals.Results: We illustrate the following types of pitfalls: confounding (by age, sex, indication, comedication), effect modification (by age), notoriety bias, masking, misclassification (by miscoding, incomplete or imprecise event retrieval), neglecting report utility, and violated independence assumption. Additionally, we show how sophisticated analyses may introduce new bias or amplify existing ones, such as collider bias or masking amplification. Conclusion: Due to its pitfalls, disproportionality analysis plays a supportive rather than decisive role in signal detection and assessment. Careful design and interpretation of disproportionality analysis, with appropriate subgrouping and clinical assessment, are essential. While subgrouping can mitigate some pitfalls, it reduces sample size and may introduce or amplify existing biases. Further development of tools to detect and mitigate biases and assess the risk of bias in published disproportionality analyses is needed.

  • Open Access

    Global Reporting Patterns of Suspected Adverse Drug Reactions and Their Relationship with a Country’s Socioeconomic Status- Insights from VigiBase Data- Study Protocol

    by Nisha Dhakal, Daniele Sartori, Anna-Riia Holmström

    Introduction Pharmacovigilance is vital for detecting Adverse Drug Reactions (ADRs), with Individual Case Safety Reports (ICSRs) serving as the primary source, despite growing interest in other data sources like electronic health records and social media. However, ICSR reporting rates remain low in low- and middle-income countries due to weak pharmacovigilance systems. Furthermore, the impact of socioeconomic factors such as health, education, and income on reporting rates has not been studied on a global scale previously. Aims To compare global ICSR reporting patterns and quantify potential differences in their characteristics across pre-defined socioeconomic strata. Methods In this observational descriptive quantitative study, numbers of ICSRs will be obtained from VigiBase for members of the World Health Organization Programme for International Drug Monitoring, from 01/01/2010 to 31/12/2022. Yearly total population data and Inequality-adjusted Human Development Index (IHDI) values will be obtained from the United Nations Development Programme (UNDP) for all countries, for the same interval. Yearly ICSR reporting rates for each country will be calculated by dividing the total ICSRs submitted to VigiBase each year, and median reporting rates computed across the study period. Similarly, the median IHDI and its dimensional indices (Health, Education, and Income) will be calculated for each country. Countries will be categorized into four human development groups based on the UNDP classification: low, medium, high, and very high. To assess the relationship between IHDI (and its dimensions) and reporting rates, a linear regression model will be applied, with adjustments made as needed based on the data characteristics. VigiPoint will also be used to compare the relative frequency of covariates between reports of low, medium, and high IHDI, against those submitted to VigiBase by very high IHDI countries. VigiPoint identifies key features for review using shrunk log odds ratios, highlighting the overrepresented characteristics of ICSRs. We will present descriptive and statistical analyses in tables and scatter plots will be used to examine the relationship between ICSR reporting rates and IHDI (and its dimensions), using the calculated median values for IHDI (and its dimensions). Trendlines will highlight temporal changes in population, IHDI, and dimensional indices. Discussion The findings will offer insights into how socioeconomic factors affect reporting practices and may guide targeted interventions to enhance global drug safety monitoring.